CHEK2-positive breast cancers in young Polish women

Clinical Cancer Research

Volumn 12, Issue 16, 2006, Pages 4832-4835

  Cybulski, Cezary ^a   Górski, Bohdan ^a   Huzarski, Tomasz ^a   Byrski, Tomasz ^a   Gronwald, Jacek ^a   Dȩbniak, Tadeusz ^a   Wokołorczyk, Dominika ^a   Jakubowska, Anna ^a   Kowalska, Elzbieta ^a   Oszurek, Oleg ^a   Narod, Steven A ^b   Lubiński, Jan ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Centre for Research on Women's Health   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 2;

ARTICLE; BREAST CANCER; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MULTIPLE CANCER; POLAND; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; INFANT, NEWBORN; MALE; MIDDLE AGED; MUTATION; POLAND; PROTEIN-SERINE-THREONINE KINASES;

EID: 33748347521     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0158     Document Type: Article

References (28)

1. Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci U S A 2000;97:10389-94.
2. Chaturvedi P, Eng WK, Zhu Y, et al. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 1999;18:4047-54.
3. CHEK2 Breast Cancer Consortium. Low-penetrance susceptibility to breast cancer due to CHEK2*1100-delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002;31:55-9.
4. Oldenburg RA, Kroeze-Jansema K, Kraan J, et al. The CHEK2 1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res 2003;63:8153-7.
5. Vahteristo P, Bartkova J, Eerola H, et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002;71:432-8.
6. CHEK2 Breast Cancer Case-Control consortium. CHEK2 1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 2004;74:1175-82.
7. Cybulski C, Gorski B, Huzarski T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004;75:1131-5.
8. Kilpivaara O, Vahteristo P, Falck J, et al. CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer 2004;111:543-7.
9. Shaag A, Walsh T, Renbaum P, et al. CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Hum Mol Genet 2005;14:555-63.
10. Lubiński J, Górski B, Huzarski T, et al. BRCA1-positive breast cancers in young women from Poland. Breast Cancer Res Treat. In press 2006.
11. Cybulski C, Huzarski T, Górski B, et al. A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res 2004;64:2677-9.
12. Sun CC, Lenoir G, Lynch H, Narod SA. In-situ breast cancer and BRCA1. Lancet 1996;348:408.
13. Lakhani SR. The pathology of familial breast cancer: Morphological aspects. Breast Cancer Res 1999;1:31-5.
14. Lakhani SR, Gusterson BA, Jacquemier J, et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 2000;6:782-9.
15. de Bock GH, Schutte M, Krol-Warmerdam EM, et al. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant. J Med Genet 2004;41:731-5.
16. Broeks A, de Witte L, Nooijen A, et al. Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers. Breast Cancer Res Treat 2004;83:91-3.
17. Johnson N, Fletcher O, Naceur-Lombardelli C, dos Santos Silva I, Ashworth A, Peto J. Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study. Lancet 2005;366:1554-7.
18. Meijers-Heijboer H, Wijnen J, Vasen H, et al. The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet 2003;72:1308-14.
19. Allinen M, Huusko P, Mantyniemi S, Launonen V, Winqvist R. Mutation analysis of the CHK2 gene in families with hereditary breast cancer. Br J Cancer 2001;85:209-12.
20. Schutte M, Seal S, Barfoot R, et al. Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am J Hum Genet 2003;72:1023-8.
21. Wu X, Webster SR, Chen J. Characterization of tumor-associated Chk2 mutations. J Biol Chem 2001;276:2971-4.
22. Falck J, Lukas C, Protopopova M, Lukas J, Selinanova G, Bartek J. Functional impact on concomitant versus alternative defects in the Chk2-53 tumour suppressor pathway. Oncogene 2001;20:5503-10.
23. Falck J, Mailand N, Syljuåsen RG, Bartek J, Lukas J. The ATM-Chk2-25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001;410:842-7.
24. Li J, Williams BL, Haire LF, et al. Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2. Mol Cell 2002;9:1045-54.
25. Bogdanova N, Enssen-Dubrowinskaja N, Feshchenko S, et al. Association of two mutations in the CHEK2 gene with breast cancer. Int J Cancer 2005;116:263-6.
26. Seppala EH, Ikonen T, Mononen N, et al. CHEK2 variants associate with hereditary prostate cancer. Br J Cancer 2003;89:1966-70.
27. Kilpivaara O, Alhopuro P, Vahteristo P, Aaltonen LA, Nevanlinna H. CHEK2 I157T associates with familial and sporadic colorectal cancer. J Med Genet 2006;43:e34.
28. Rudd MF, Sellick GS, Webb EL, Catovsky D, Houlston RS. Variants in the ATM-BRCA2-2 axis predispose to chronic lymphocytic leukaemia. Blood 2006;108:638-44.